Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
Diabetes Care
|
April 24, 2001
Cardiovascular morbidity and mortality associated with the metabolic syndrome
B Isomaa, P Almgren, T Tuomi, et al.
Diabetologia
|
August 10, 2011
Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study
P Almgren, M Lehtovirta, B Isomaa, et al.
Diabetologia
|
November 1, 2012
Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes
S Alkayyali, M Lajer, H Deshmukh, et al.
Diabetologia
|
April 18, 2009
Assessing the effect of interaction between an FTO variant (rs9939609) and physical activity on obesity in 15,925 Swedish and 2,511 Finnish adults
A Jonsson, F Renström, V Lyssenko, et al.
Diabetologia
|
October 16, 2007
Polymorphisms in the gene encoding the voltage-dependent Ca(2+) channel Ca (V)2.3 (CACNA1E) are associated with type 2 diabetes and impaired insulin secretion
J Holmkvist, D Tojjar, P Almgren, et al.
European Journal of Haematology
|
February 1, 1990
Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group
I P Palva, P Ahrenberg, K Ala Harja, et al.
Diabetologia
|
May 20, 2008
Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle
T Rönn, P Poulsen, O Hansson, et al.
European Journal of Haematology
|
October 1, 1989
Treatment of multiple myeloma in old patients. Finnish Leukaemia Group
I P Palva, P Ahrenberg, K Ala-Harja, et al.
European Journal of Haematology
|
August 1, 1993
Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group
I P Palva, K Ala-Harja, A Almqvist, et al.
European Journal of Haematology
|
January 1, 1987
Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group
I P Palva, P Ahrenberg, K Ala-Harja, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
Diabetes Care
|
April 24, 2001
Cardiovascular morbidity and mortality associated with the metabolic syndrome
B Isomaa, P Almgren, T Tuomi, et al.
Diabetologia
|
August 10, 2011
Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study
P Almgren, M Lehtovirta, B Isomaa, et al.
Diabetologia
|
November 1, 2012
Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes
S Alkayyali, M Lajer, H Deshmukh, et al.
Diabetologia
|
April 18, 2009
Assessing the effect of interaction between an FTO variant (rs9939609) and physical activity on obesity in 15,925 Swedish and 2,511 Finnish adults
A Jonsson, F Renström, V Lyssenko, et al.
Diabetologia
|
October 16, 2007
Polymorphisms in the gene encoding the voltage-dependent Ca(2+) channel Ca (V)2.3 (CACNA1E) are associated with type 2 diabetes and impaired insulin secretion
J Holmkvist, D Tojjar, P Almgren, et al.
European Journal of Haematology
|
February 1, 1990
Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group
I P Palva, P Ahrenberg, K Ala Harja, et al.
Diabetologia
|
May 20, 2008
Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle
T Rönn, P Poulsen, O Hansson, et al.
European Journal of Haematology
|
October 1, 1989
Treatment of multiple myeloma in old patients. Finnish Leukaemia Group
I P Palva, P Ahrenberg, K Ala-Harja, et al.
European Journal of Haematology
|
August 1, 1993
Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group
I P Palva, K Ala-Harja, A Almqvist, et al.
European Journal of Haematology
|
January 1, 1987
Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group
I P Palva, P Ahrenberg, K Ala-Harja, et al.
Page
of 7